Somatic mutations in <i>CALR</i> gene have been reported in 60%-88% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF) who are negative for <i>JAK2</i> and <i>MPL</i> mutations. This evidence concerns the gene JAK2 and essential thrombocythemia.